Regenerative Medicine

BioCardia secures key regulatory backing in the US and Japan, but the real story may be its pivot to a platform provider for the entire cardiac biologics field.

With key FDA backing and promising clinical data, Allogene Therapeutics is advancing a vision where complex cell therapies are not just for major medical centers.

With breakthrough dialysis data and a new heart-mending vessel, Humacyte is balancing radical innovation with commercial reality. Is this the future of medicine?

BioStem Technologies' move from OTC to Nasdaq marks a pivotal moment, promising greater capital access and visibility for its innovative perinatal allografts.

A landmark study on equicenta® CTM shows it nearly triples a horse's odds of returning to performance, offering a ready-to-use solution that challenges the status quo.

A French biotech's breakthrough in topical mRNA delivery could turn skin into a programmable interface, disrupting dermatology and the multi-billion dollar beauty industry.

A revenue dip masks a calculated pivot. UTHR is betting its future not just on new drugs, but on a revolutionary plan to manufacture human organs.

By assembling a 'dream team' of scientific advisors, INmune Bio isn't just advancing a drug; it's fortifying the very structure of cell therapy development.

A new study on umbilical cord allografts offers hope for chronic neck pain, but a closer look reveals the complex scientific and regulatory networks that will define its future.

A Cleveland-based innovator rebrands, signaling a major shift from passive wound care to active biomaterials designed to guide regeneration and defeat infection.

Pluri's subsidiary Cellav just won UK approval for its aesthetic product. But the real story is the science and a market potentially 4x larger than stated.

Pacira BioSciences de-risks its promising knee osteoarthritis gene therapy by solving the manufacturing puzzle, a key step from lab to market for millions.

A Tokyo innovator just hit Nasdaq via a SPAC. Is its vertically integrated model the key to unlocking the $67B longevity market or just another biotech gamble?

AcroCyte Therapeutics secures funding from the US government's 'DARPA for Health,' validating its unique organoid tech and signaling a strategic push to solve organ shortages.

Houston-based TYBR Health lands $30M to scale its B3 GEL System, a novel hydrogel aiming to shift orthopedic surgery from mere repair to managed recovery.

Kolon TissueGene's revolutionary knee therapy, once a beacon of hope, fails a pivotal Phase 3 trial, raising questions about its future and the broader field.

South Korea's HIGHER Corp. unveils preclinical data for HILO WAVE®, a dual-hyaluronic acid booster that may bypass the inflammatory pathways of competitors.

A new treatment, Junera™, isn't just about smoother skin. It signals a major shift in how the beauty industry operates, blending advanced biostimulation with powerful physician networks.

Revel's new enzyme reverses a hallmark of aging. This isn't just a lab success; it's a strategic move challenging the very definition of 'irreversible'.

A landmark public-private partnership in Vietnam pioneers bioengineered corneas, promising to restore sight to millions and signaling a new era for ASEAN biotech.